Wiener klinische Wochenschrift

, Volume 128, Supplement 2, pp 73–79 | Cite as

Diabetische Neuropathie

  • Monika LechleitnerEmail author
  • Heidemarie Abrahamian
  • Claudia Francesconi
  • Markus Kofler
leitlinien für die praxis


Der Begriff der diabetischen Neuropathie umfasst Mono- und Polyneuropathieformen, die diabetische Plexopathie, Radikulopathie und die autonome Neuropathie. Die Leitlinienempfehlungen beschreiben die klinischen Symptome und diagnostischen Möglichkeiten sowie die Therapiemaßnahmen, insbesondere bei der schmerzhaften Form der sensomotorischen Neuropathie.


Diabetische Neuropathie 

Diabetic neuropathy


These are the guidelines for diagnosis and treatment of diabetic neuropathy. This diabetic late complication comprises a number of mono- and polyneuropathies, plexopathies, radiculopathies and autonomic neuropathy. The position statement summarizes characteristic clinical symptoms and techniques for diagnostic assessment of diabetic neuropathy. Recommendations for the therapeutic management of diabetic neuropathy, especially for the control of pain in sensorimotor neuropathy, are provided.


Diabetic neuropathy 


Einhaltung ethischer Richtlinien


M. Lechleitner hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Honorare erhalten: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline Pharma, Eli Lilly, Merck Sharp & Dome, Novartis, Novo Nordisk, Pfizer, sanofi-sventis, Takeda.

H. Abrahamian hat von folgenden Unternehmen, die auch fördernde Mitglieder der ÖDG sind, Forschungsunterstützungen und/oder Honorare erhalten: Abbott, Bristol-Myers Squibb, Germania Pharmazeutika, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, sanofi-aventis, Takeda.

C. Francesconi und M. Kofler haben keinen Interessenkonflikt.


  1. 1.
    Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boultin AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–4.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRefGoogle Scholar
  3. 3.
    American Diabetes Association. Microvascular complications and foot care. Diabetes Care. 2015;38(Suppl 1):S58–66.CrossRefGoogle Scholar
  4. 4.
    Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients. The Oslo study. Diabetologia. 1994;37:579–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Bolton CF, Remtulla H, Toth B, Bernardi L, Lindsay RM, Maryniak O, Burton SR. Distinctive electrophysiological features of denervated muscle in uremic patients. J Clin Neurophysiol. 1997;14:539–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy – report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve. 2011;43:910–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Callaghan BC, Cheng HAT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatment. Lancet Neurol. 2012;11:521–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Diabetes Control and Complication Trial Research Group. The effects of intensive treatment of diabetes on the developmentand progressive of long term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  10. 10.
    Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157–63.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American Veterans with type 2 diabetes. N Engl J Med. 2009;8:129–39.CrossRefGoogle Scholar
  12. 12.
    Dyck PJ, Karnes JL, O’Brien PC, et al. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43:817–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Feldman EL. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15:119–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabetes Metab. 2009;35:12–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Hoeldike RD, Bryner KD, Van Dyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res. 2011;21:19–28.CrossRefGoogle Scholar
  18. 18.
    Holman RR, Paul SK, Bethal MA, et al. 10-years follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies ISJ, Polydefkis M, Smith AG, Sommer C, Valls-Solé J. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903–e49.CrossRefPubMedGoogle Scholar
  20. 20.
    Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46:683–8.PubMedGoogle Scholar
  21. 21.
    Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial. Diabetes Care. 2006;29:340–4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complication study. Diabetes. 1989;38:1456–61.CrossRefPubMedGoogle Scholar
  23. 23.
    McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377–85.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Meijer JW, Bosma E, Leprandt JD, Links TP, Smit AJ, Stewart RE, Van Der Hoeven JH, Hoogenberg K. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptoms and diabetic neuropathy examination score. Diabetes Care. 2003;26:697–701.CrossRefPubMedGoogle Scholar
  25. 25.
    Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;8:CD007076.Google Scholar
  26. 26.
    Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes- Weinstein monofilaments. Phys Ther. 1996;76:68–71.PubMedGoogle Scholar
  27. 27.
    Papanas N, Paschos P, Papazoglu D, Papatheodorou K, Paletas K, Maltezos E, Tsapas A. Accuracy of the Neuropad test for the diagnosis of distal symmetric polyneuropathy in type 2 diabetes. Diabetes Care. 2011;34:1378–82.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rahman M, Griffin SJ, Rathman W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-bases comparison of four measures. Diabet Med. 2003;20:368–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose levels:the Stockholm Diabetes Intervention Study (SDIS) at 10-years follow up. Diabetologia. 1996;31:1483–8.CrossRefGoogle Scholar
  30. 30.
    Sima AA, Sugimoto K. Experimental diabetic neuropathy. An update. Diabetologia. 1999;42:773–88.CrossRefPubMedGoogle Scholar
  31. 31.
    Snedcor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167–84.CrossRefGoogle Scholar
  32. 32.
    Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic neuropathy. Diabetes Metab Res Rev. 2012;28 Suppl 1:8–14.CrossRefPubMedGoogle Scholar
  33. 33.
    Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tesfaye S, Vileikyte L, Rayman G, et al. On behalf of The Toronto Expert Panel on Diabetic Neuropathy. Diabetes Metab Res Rev. 2011;27:629–38.CrossRefPubMedGoogle Scholar
  35. 35.
    UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and rate of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;12:837–63.Google Scholar
  36. 36.
    Van de Pollyranse LV, Valk GD, Renders CM, Heine RJ, Eijk JTM. Longitudinal assessment of the development of diabetic polyneuropathies and associated risk factors. Diabetic Med. 2003;19:771–9.Google Scholar
  37. 37.
    Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanism as therapeutic targets. Nat Rev Neurol. 2011;7:573–83.CrossRefPubMedGoogle Scholar
  38. 38.
    Vinik AI, Maser RE, Mitchell BD, Freema R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.CrossRefPubMedGoogle Scholar
  39. 39.
    Yagihashi S, Yamagishi SI, Wada RI, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain. 2001;124:2448–58.CrossRefPubMedGoogle Scholar
  40. 40.
    Young MJ, Boulton AJM, MacIEOD, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital population. Diabetologia. 1993;36:150–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Ziegler D. Treatment of diabetic neuropathy: update 2006. Ann N Y Acad Sci. 2006;1084:250–68.CrossRefPubMedGoogle Scholar
  42. 42.
    Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care. 2008;31 Suppl 2:255–61.CrossRefGoogle Scholar
  43. 43.
    Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep. 2011;3:216–27.Google Scholar
  44. 44.
    Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complications. 2015;29:146–56.CrossRefPubMedGoogle Scholar
  45. 45.
    Ziegler D, Gries FA. Epidemiologie der peripheren diabetischen Neuropathie. Diabetes Stoffwechs. 1992;1:24–8.Google Scholar
  46. 46.
    Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck. KORA study group: neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Survey S2 and S3. Pain Med. 2009;10:393–400.CrossRefPubMedGoogle Scholar
  47. 47.
    Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the Nathan 1 trial. Diabetes Care. 2011;34:2054–60.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve. 2007;36:144–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Monika Lechleitner
    • 1
    Email author
  • Heidemarie Abrahamian
    • 2
  • Claudia Francesconi
    • 3
  • Markus Kofler
    • 4
  1. 1.Interne AbteilungLandeskrankenhaus Hochzirl - NattersHochzirlÖsterreich
  2. 2.Internistisches Zentrum, Sozialmedizinisches Zentrum Baumgartner HöheOtto-Wagner-SpitalWienÖsterreich
  3. 3.Sonderkrankenanstalt Rehabilitationszentrum AllandAllandÖsterreich
  4. 4.Abteilung für NeurologieLandeskrankenhaus HochzirlHochzirlÖsterreich

Personalised recommendations